Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy (Q36393138)

13 August 2017

Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy (English)

1 reference

13 August 2017

5

Jean-Michel Foidart

0 references

Bo von Schoultz

Rena Vassilopoulou-Sellin

7

object named as

Bo von Schoultz

0 references

8

object named as

Rena Vassilopoulou-Sellin

0 references

Matthias W. Beckmann

4

object named as

Matthias W Beckmann

1 reference

13 August 2017

6

Piero Sismondi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22251615

22 December 2024

author name string

Peter Kenemans

2

1 reference

13 August 2017

Cheng Har Yip

3

1 reference

13 August 2017

Rachid El Galta

9

1 reference

13 August 2017

Eugenie Van Lieshout

10

1 reference

13 August 2017

Mirjam Mol-Arts

11

1 reference

13 August 2017

Juan Planellas

12

1 reference

13 August 2017

Ernst Kubista

13

1 reference

13 August 2017

Nigel J. Bundred

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22251615

22 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22251615

22 December 2024

publication date

17 January 2012

1 reference

full work available at URL

13 August 2017

https://breast-cancer-research.biomedcentral.com/counter/pdf/10.1186/bcr3097

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22251615

https://europepmc.org/articles/PMC3496130

22 December 2024

file format

HyperText Markup Language

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22251615

https://europepmc.org/articles/PMC3496130?pdf=render

22 December 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22251615

https://link.springer.com/content/pdf/10.1186/bcr3097.pdf

22 December 2024

1 reference

https://link.springer.com/article/10.1186/bcr3097/fulltext.html

22 December 2024

file format

HyperText Markup Language

1 reference

22 December 2024

published in

Breast Cancer Research

1 reference

13 August 2017

14

1 reference

13 August 2017

1

1 reference

13 August 2017

R13

1 reference

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

The effects of tibolone in older postmenopausal women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

A referent bone mineral density database for Chinese American women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

Breast-cancer adjuvant therapy with zoledronic acid

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study

28 June 2018

1 reference

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

21 January 2018

1 reference

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

21 January 2018

1 reference

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

21 January 2018

1 reference

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

21 January 2018

1 reference

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis

21 January 2018

1 reference

Bone mineral density and mass in a cross-sectional study of white and Asian women

21 January 2018

1 reference

Multiple genetic loci for bone mineral density and fractures

21 January 2018

1 reference

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3496130

Spinal trabecular bone loss and fracture in American and Japanese women

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22251615

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/BCR3097

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference

13 August 2017

1 reference